A 48-year-old @entity1 was admitted with chronic @entity2800 in November, 1996 and was treated with @entity1862 (HU), because of marked leukocytosis; WBC 404,000/microliter. On January 29, 1997, administration of HU was stopped, and treatment of alpha-interferon ( @entity3027 ) was started with 6x 10(6)U, every day. However, the WBC count rose from 19,600/microliter to 56,800/microliter, and the combination of IFN and 2,000 mg of HU was started on February 4. The dose of HU was reduced to 500 mg on February 27, and the IFN administration was reduced to 3 times a week from April 4, because the WBC count was less than 10,000/microliter. @entity3043 was revealed in May. The bone marrow biopsy specimen demonstrated marked hypoplastic changes, and chromosome analysis of bone marrow cells showed Philadelphia chromosome in all 20 metaphases. Treatment was interrupted for 7 months, but hematologic parameters did not recover. There were 9 cases reported in detail with @entity236 induced by IFN. One @entity1 received IFN alone and 8 patients received anti- @entity5 drugs before treatment of IFN. We concluded that great care must be taken for IFN treatment of @entity1860 .

[ @entity1860 with long-term hypoplasia induced by alpha-interferon and XXXX ].

@entity1 :: ('9606', 'Species') :: ['woman', 'patient'] @entity1862 :: ('MESH:D006918', 'Chemical') :: ['hydroxyurea'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity2800 :: ('MESH:D007951', 'Disease') :: ['myelogenous leukemia'] @entity236 :: ('MESH:D001855', 'Disease') :: ['bone marrow hypoplasia'] @entity3043 :: ('MESH:D010198', 'Disease') :: ['Pancytopenia'] @entity3027 :: ('3439', 'Gene') :: ['IFN alpha'] @entity1860 :: ('MESH:D015464', 'Disease') :: ['CML']
@entity1862 :: (MESH:D006918,Chemical) :: ['hydroxyurea']
